Form 4: Relay Therapeutics Director Jami Rubin Acquires Stock Options

Director Jami Rubin of Relay Therapeutics, Inc. reports the acquisition of stock options for 102,225 shares on June 3, 2024.

Summary

• Jami Rubin, a director of Relay Therapeutics, Inc., filed a Form 4 on June 5, 2024, reporting a transaction.
• On June 3, 2024, Rubin acquired stock options for 102,225 shares of Relay Therapeutics common stock at an exercise price of $6.79.
• These options vest fully on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders following the grant date.
• Following the reported transaction, Rubin directly owns options for 102,225 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing regarding stock option grants to a director.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to monitor the actions of those with privileged information.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's perspective on the company's value.

Key Dates